Non-steroidal anti-inflammatory drugs and the risk of atrial fibrillation: A population-based follow-up study

BMJ Open

Volumn 4, Issue 4, 2014, Pages

  Krijthe, Bouwe P ^a,b   Heeringa, Jan ^a   Hofman, Albert ^a   Franco, Oscar H ^a   Stricker, Bruno H ^a,b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Consortium for Healthy Aging ^*  (Netherlands)

^c Healthcare Inspectorate   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; EPIDEMIOLOGY; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84899072715     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004059     Document Type: Article

References (30)

1. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36:1115-19. (Pubitemid 40803473)
2. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-5. (Pubitemid 36736633)
3. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359-64. (Pubitemid 35223606)
4. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 2007;49:986-92.
5. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52. (Pubitemid 28446646)
6. van der Hooft CS, Heeringa J, van Herpen G, et al. Drug-induced atrial fibrillation. J Am Coll Cardiol 2004;44:2117-24. (Pubitemid 39585198)
7. van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006;166:1016-20.
8. De Caterina R, Ruigomez A, Rodriguez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med 2010;170:1450-5.
9. Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 2011;343:d3450.
10. Back M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J 2012;33:1928-33.
11. Haag MD, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008;168:1219-24. (Pubitemid 351831405)
12. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102. (Pubitemid 40365350)
13. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80. (Pubitemid 40365348)
14. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91. (Pubitemid 40365349)
15. van den Hondel KE, Eijgelsheim M, Ruiter R, et al. Effect of short-term NSAID use on echocardiographic parameters in elderly people: a population-based cohort study. Heart 2011;97:540-3.
16. Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol 2011;26:657-86.
17. Leening MJ, Kavousi M, Heeringa J, et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 2012;27:173-85.
18. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
19. Kors JA, van Herpen G, Wu J, et al . Validation of a new computer program for Minnesota coding. J Electrocardiol 1996;29(Suppl): 83-8. (Pubitemid 27051639)
20. van Bemmel JH, Kors JA, van Herpen G. Methodology of the modular ECG analysis system MEANS. Methods Inf Med 1990;29:346-53. (Pubitemid 20311457)
21. Willems JL, Abreu-Lima C, Arnaud P, et al. The diagnostic performance of computer programs for the interpretation of electrocardiograms. N Engl J Med 1991;325:1767-73.
22. Halligan SC, Gersh BJ, Brown RD Jr, et al. The natural history of lone atrial flutter. Ann Intern Med 2004;140:265-8.
23. Lelorier P, Humphries KH, Krahn A, et al. Prognostic differences between atrial fibrillation and atrial flutter. Am J Cardiol 2004;93:647-9. (Pubitemid 38293082)
24. WHO. Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2012. Oslo, 2011.
25. Remme WJ, Swedberg K; Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60. (Pubitemid 32801300)
26. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam Study. Eur Heart J 1999;20:447-55. (Pubitemid 29116541)
27. Dehghan A, Kardys I, de Maat MP, et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007;56:872-8. (Pubitemid 46348467)
28. Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010;25:245-51.
29. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001;110(Suppl 3A):33S-42S. (Pubitemid 32155401)
30. Lindhardsen J, Ahlehoff O, Gislason GH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 344:e1257.